Market Cap 747.67M
Revenue (ttm) 81.39M
Net Income (ttm) -114.20M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -140.31%
Debt to Equity Ratio 0.00
Volume 1,094,800
Avg Vol 465,256
Day's Range N/A - N/A
Shares Out 81.45M
Stochastic %K 90%
Beta 1.27
Analysts Strong Sell
Price Target $26.00

Company Profile

MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also develops AAV-AQP1 for radiation-induced grade 2/3 radiation-induced xerostomia, as well as for Sjogren's syndrome; AAV-GAD in Phase 2 trial for Parkinson's disease; AAV-RP...

Industry: Biotechnology
Sector: Healthcare
Phone: 646 860 7985
Address:
655 Third Avenue, Suite 1115, New York, United States
slinghook67
slinghook67 Apr. 2 at 2:14 AM
$MGTX Another clue from David Berry from Averin re: Hologen... lots of strong correlations in this to what Hologen is building..... Bring on the SPAC.
3 · Reply
MGTX
MGTX Apr. 1 at 11:19 PM
$MGTX My forecast. First real possibility of a buyout comes after the release of the pivotal phase 2 xerostomia data later this year. Hopefully by then we might have some indication of how the halogen Parkinson's, you know, phase three is proceeding, but probably not. Second possibility. the mid-2027 GLP-1 trial data is when MGTX definitively gets bought out Assuming that it all goes well and is positive. The two real prices that it could get bought out for is four to five billion if they're only looking at the xerostomia and the phase 3 Parkinson's and the manufacturing facilities and the rest of the pipeline. But if the GLP-1 trial data is positive and proves that they have in humans conquered gene regulation that is titratable with an oral small molecule, then all bets are off, and I think we're going to get a $10 billion, $12 billion, or more buyout.
2 · Reply
Bogy99
Bogy99 Apr. 1 at 5:32 PM
$MGTX is this time different ? I may have even used this headline in the past. We always have trouble clearing $9/$10 ceiling and fall back to around $7. I do think this time is different , however, for the following reasons. 1 ) we have an actual date for the next catalyst. April 16th will be good news on durability and size of market. 2) Short Interest is high (although seems shorts have started to cover since my “save your family “ message). There’s way better shorts out there than this stock, time to move on if you’re short. 3) LLY will be dumping a boat load of cash on us any day now. Market doesn’t react until cash in the books. Stock will go up on this news even though we already know it’s money in the bank. For these three reasons, I think we will finally break that glass ceiling and use that $10 area for future support. Am I wrong ? Time will tell.
3 · Reply
ErnieWorthing84
ErnieWorthing84 Apr. 1 at 2:14 PM
$MGTX https://www.reuters.com/sustainability/boards-policy-regulation/rare-disease-advocacy-group-urges-trump-administration-restore-fda-clarity-2026-04-01/
0 · Reply
Helpmrwizard
Helpmrwizard Apr. 1 at 2:00 PM
$MGTX fascinating! These institutions will not write out of the money calls; guess it was too hard to build a long position in MeiraGTx
0 · Reply
slinghook67
slinghook67 Mar. 31 at 11:42 PM
$MGTX A question for the group. If you're short MeiraGTx heading into their scheduled call on April 16th and you don't close your position, what could possibly be your short thesis? It's a virtual certainty that Meira's update is going to be stellar. After all, there's no way that the FDA would have granted them a BTD for Xerostomia if they weren't convinced about the strength and durability of the 3 year Phase 1 data. Nor would Meira specifically pre-announce a "commercial update" for the call on the 16th. You simply don't do that if you're reporting bad news. All that to say, what's the short thesis if someone stays short through the 16th?
2 · Reply
banner20
banner20 Mar. 31 at 7:05 PM
$MGTX who.would be the buyout target here.... Lilly or JnJ
1 · Reply
Helpmrwizard
Helpmrwizard Mar. 31 at 4:34 PM
@ErnieWorthing84 sounds like we will be hearing more about this $MGTX ”pipeline within a pipeline” opportunity on April 16th
1 · Reply
ErnieWorthing84
ErnieWorthing84 Mar. 31 at 4:08 PM
$MGTX https://www.fiercebiotech.com/biotech/astellas-axes-early-sjogrens-trial-latest-setback-autoimmune-disease-community?utm_medium=email&utm_source=nl&utm_campaign=LS-NL-FierceBiotech&oly_enc_id=0316A4496778F6E
1 · Reply
vu_jade
vu_jade Mar. 31 at 1:45 PM
$MGTX walk softly But carry a big stick
0 · Reply
Latest News on MGTX
MeiraGTx Holdings: Gaining Regulatory Focus

Mar 25, 2025, 10:50 AM EDT - 1 year ago

MeiraGTx Holdings: Gaining Regulatory Focus


MeiraGTx Holdings: Behind The Recent Rally

Dec 3, 2024, 2:18 PM EST - 1 year ago

MeiraGTx Holdings: Behind The Recent Rally


MeiraGTx to Participate in Upcoming Investor Conferences

Apr 24, 2024, 4:30 PM EDT - 2 years ago

MeiraGTx to Participate in Upcoming Investor Conferences


MeiraGTx: Bota-Vec Program Advancing With Milestones Being Met

Feb 15, 2024, 8:23 AM EST - 2 years ago

MeiraGTx: Bota-Vec Program Advancing With Milestones Being Met


MeiraGTx shares jump as Sanofi invests in gene therapy

Oct 30, 2023, 8:28 AM EDT - 2 years ago

MeiraGTx shares jump as Sanofi invests in gene therapy

SNY


slinghook67
slinghook67 Apr. 2 at 2:14 AM
$MGTX Another clue from David Berry from Averin re: Hologen... lots of strong correlations in this to what Hologen is building..... Bring on the SPAC.
3 · Reply
MGTX
MGTX Apr. 1 at 11:19 PM
$MGTX My forecast. First real possibility of a buyout comes after the release of the pivotal phase 2 xerostomia data later this year. Hopefully by then we might have some indication of how the halogen Parkinson's, you know, phase three is proceeding, but probably not. Second possibility. the mid-2027 GLP-1 trial data is when MGTX definitively gets bought out Assuming that it all goes well and is positive. The two real prices that it could get bought out for is four to five billion if they're only looking at the xerostomia and the phase 3 Parkinson's and the manufacturing facilities and the rest of the pipeline. But if the GLP-1 trial data is positive and proves that they have in humans conquered gene regulation that is titratable with an oral small molecule, then all bets are off, and I think we're going to get a $10 billion, $12 billion, or more buyout.
2 · Reply
Bogy99
Bogy99 Apr. 1 at 5:32 PM
$MGTX is this time different ? I may have even used this headline in the past. We always have trouble clearing $9/$10 ceiling and fall back to around $7. I do think this time is different , however, for the following reasons. 1 ) we have an actual date for the next catalyst. April 16th will be good news on durability and size of market. 2) Short Interest is high (although seems shorts have started to cover since my “save your family “ message). There’s way better shorts out there than this stock, time to move on if you’re short. 3) LLY will be dumping a boat load of cash on us any day now. Market doesn’t react until cash in the books. Stock will go up on this news even though we already know it’s money in the bank. For these three reasons, I think we will finally break that glass ceiling and use that $10 area for future support. Am I wrong ? Time will tell.
3 · Reply
ErnieWorthing84
ErnieWorthing84 Apr. 1 at 2:14 PM
$MGTX https://www.reuters.com/sustainability/boards-policy-regulation/rare-disease-advocacy-group-urges-trump-administration-restore-fda-clarity-2026-04-01/
0 · Reply
Helpmrwizard
Helpmrwizard Apr. 1 at 2:00 PM
$MGTX fascinating! These institutions will not write out of the money calls; guess it was too hard to build a long position in MeiraGTx
0 · Reply
slinghook67
slinghook67 Mar. 31 at 11:42 PM
$MGTX A question for the group. If you're short MeiraGTx heading into their scheduled call on April 16th and you don't close your position, what could possibly be your short thesis? It's a virtual certainty that Meira's update is going to be stellar. After all, there's no way that the FDA would have granted them a BTD for Xerostomia if they weren't convinced about the strength and durability of the 3 year Phase 1 data. Nor would Meira specifically pre-announce a "commercial update" for the call on the 16th. You simply don't do that if you're reporting bad news. All that to say, what's the short thesis if someone stays short through the 16th?
2 · Reply
banner20
banner20 Mar. 31 at 7:05 PM
$MGTX who.would be the buyout target here.... Lilly or JnJ
1 · Reply
Helpmrwizard
Helpmrwizard Mar. 31 at 4:34 PM
@ErnieWorthing84 sounds like we will be hearing more about this $MGTX ”pipeline within a pipeline” opportunity on April 16th
1 · Reply
ErnieWorthing84
ErnieWorthing84 Mar. 31 at 4:08 PM
$MGTX https://www.fiercebiotech.com/biotech/astellas-axes-early-sjogrens-trial-latest-setback-autoimmune-disease-community?utm_medium=email&utm_source=nl&utm_campaign=LS-NL-FierceBiotech&oly_enc_id=0316A4496778F6E
1 · Reply
vu_jade
vu_jade Mar. 31 at 1:45 PM
$MGTX walk softly But carry a big stick
0 · Reply
AimSmall
AimSmall Mar. 31 at 1:20 PM
$MGTX nice mention, didn't download the whole article but if anyone else has access, would love to hear more!https://www.globenewswire.com/news-release/2026/03/27/3263828/0/en/AI-Is-Reshaping-Neuroprotective-Drug-Discovery-Market-New-BCC-Research-Pulse-Report-Maps-the-Investment-and-Innovation-Landscape.html
0 · Reply
slinghook67
slinghook67 Mar. 31 at 12:15 PM
$MGTX Big pharma M&A continues to rage as 2 big deals announced this morning. Centessa is being acquired for 1 lead Narcolepsy asset that while showing "best in class" efficacy, will compete against a dozen drugs already on the market. They've got zero revenue, limited cash, a thin pipeline outside of their lead asset, no manufacturing assets, and yet they went for $6B. Our day will come....
0 · Reply
AimSmall
AimSmall Mar. 30 at 4:07 PM
$MGTX Anyone else notice the 10-K section on the manufacturing section with Hologen?
1 · Reply
d_risk
d_risk Mar. 30 at 2:55 PM
$MGTX - MeiraGTx Holdings plc - 10K - Updated Risk Factors MGTX adds new risks around closing and funding a major Hologen deal, extended and restructured Perceptive notes, integration of the Smart Immune acquisition, evolving U.S./EU drug pricing and regulatory overhauls, data transfer uncertainty, and operational, legal and competitive exposure from expanding use of AI. #Biotechnology #PharmaceuticalPricing #RegulatoryRisk #AIIntegration #MergersAndAcquisitions 🟢 Added 🟠 Removed https://d-risk.ai/MGTX/10-K/2026-03-30
0 · Reply
ErnieWorthing84
ErnieWorthing84 Mar. 30 at 1:02 PM
$MGTX Have received 105 of 430 from Hologen. Meira now holds 500,000 shares. Explains why phase 3 hasn't moved yet...
1 · Reply
slinghook67
slinghook67 Mar. 30 at 1:01 PM
$MGTX This is good news for Hologen (and by extension Meira), as it validates that Big Pharma will pay multi‑billion‑dollar economics for AI that accelerates or improves R&D.... I would also argue that what Hologen is building specific to trial optimization will be even more valuable downstream vs. pure AI for drug development.....
1 · Reply
ErnieWorthing84
ErnieWorthing84 Mar. 30 at 12:56 PM
$MGTX So, the Lilly actually includes a new ROFN: " Lilly has a right of first negotiation for use of our proprietary riboswitch technology in the field of ophthalmological gene editing."
0 · Reply
waterlock
waterlock Mar. 30 at 8:54 AM
$MGTX Don't see xlrp progress. I think this is will be abandoned by JnJ. Also, no mentions of RiboCar and the ZipBioworks progress. other than these, I'm optimistic of the development.
1 · Reply
ErnieWorthing84
ErnieWorthing84 Mar. 29 at 10:20 PM
$MGTX Good benchmark for valuing the ribo-leptin they’re INDing this year. The only existing treatment was bought for 1.5 b in 2023 (technically a tad lower than that because of the other CRVs drug, but inflation rounds it out) https://www.chiesi.com/en/chiesi-farmaceutici-s.p.a.-to-acquire-amryt-pharma-plc/
1 · Reply
OmegaOrbit95
OmegaOrbit95 Mar. 29 at 6:41 PM
$MGTX biotech tape can rip out of nowhere so watch for confirm if volume returns
1 · Reply
MGTX
MGTX Mar. 28 at 11:39 AM
$MGTX https://seekingalpha.com/article/4856666?gt=3e5b92750343effa
1 · Reply
MGTX
MGTX Mar. 28 at 11:34 AM
$MGTX https://seekingalpha.com/article/4886657?gt=3776fbeb92f3bec7
0 · Reply